Myocardial Ischemia and Transfusion (MINT) - DCC
Myocardial Ischemia and Transfusion (MINT) - DCC
批准号:
10290738
负责人:
Maria Mori Brooks
金额:
$75.05万
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2024-08-31
关键词:
AcuteAcute myocardial infarctionAddressAdoptionAdverse eventAnemiaAutomobile DrivingBlood TransfusionCanadaCardiovascular systemCarrying CapacitiesCessation of lifeClassificationClinicalClinical InvestigatorClinical TrialsClinical Trials Data Monitoring CommitteesCommunitiesCongestive Heart FailureCoronary heart diseaseDataData AnalysesData CollectionData Coordinating CenterData ReportingData SetDatabasesDropsElectrocardiogramEnsureEventExclusion CriteriaGuidelinesHemoglobinHemoglobin concentration resultHospitalsHuman ResourcesImmunityIncidenceInfrastructureIntentionInterventionLeadershipLength of StayManualsManuscriptsMeasuresMediator of activation proteinMedicalMethodsMonitorMyocardial InfarctionMyocardial IschemiaNational Heart, Lung, and Blood InstituteOutcomeOxygenPatient-Focused OutcomesPatientsPilot ProjectsPneumoniaPositioning AttributePreparationProceduresProcessProtocols documentationQuality ControlQuality IndicatorQuality of CareRandomizedRandomized Clinical TrialsRecurrenceReportingRiskSchemeShapesSiteSpecific qualifier valueStatistical Data InterpretationSystemThromboembolismTrainingTransfusionTreatment EffectivenessUncertaintyUnited StatesUnited States National Institutes of HealthUniversitiesVariantWood materialWritingadverse outcomebaseclinical centerclinical practiceclinical research sitedata centersdata managementdata qualitydata resourcedesignepidemiologic dataexperiencehigh riskhospital readmissioninclusion criteriamedical schoolsmortalitymortality riskoperationpatient populationpilot trialpragmatic trialsystematic reviewthrombotictreatment strategyuser-friendly
中文摘要
项目总结
英文摘要
PROJECT SUMMARY
Accumulating evidence from clinical trials suggests that a restrictive transfusion strategy is safe in most clinical
settings. However, a low oxygen carrying capacity from moderate anemia may be deleterious in patients with
cardiac ischemia. The potential for harm associated with anemia in patients with acute symptomatic coronary
disease is supported by pathophysiological data that maintaining higher hemoglobin levels could benefit the
ischemic heart by increasing oxygen delivery. Furthermore, results of the 110 patient MINT pilot trial found
that all-cause mortality at 30 days was less frequent with a liberal transfusion strategy, 1 patient (1.8%),
compared with a restrictive transfusion strategy, 7 patients (13.0%), (p=0.032). Systematic reviews of clinical
trials evaluating transfusion strategies in patients with known ischemic heart disease document the absence of
high quality data which has resulted in an ongoing controversy. The lack of high quality evidence to guide
transfusions in patients with acute myocardial infarction has been cited in several major guidelines as well as
by an NIH expert panel. Despite this, blood transfusions are being used as a negative indicator of quality of
care by major organizations driving the adoption of restrictive strategies. The potential for adverse outcomes is
real and immediate.
In this multicenter pragmatic trial, we will activate 40 clinical centers and will randomly allocate 3500 patients at
risk of myocardial ischemia with acute myocardial infarction and hemoglobin concentration less than 10 g/dL to
be treated either according to a restrictive or liberal blood transfusion strategy. Our Primary Aim will be to
determine whether a liberal transfusion threshold strategy (10 g/dL) is superior and will result in lower rates of
either all cause mortality or acute myocardial infarction within 30 days following randomization as compared
with a restrictive transfusion threshold strategy (8 g/dL). Our secondary aims will examine the effect of a liberal
transfusion strategy compared with a restrictive transfusion strategy on adverse outcomes of transfusion
related to volume overload, thrombotic risk and modified immunity. We will compare 30-day rates of
congestive heart failure, thromboembolism, and pneumonia. We will also compare rates of 30-day death,
cardiovascular death, myocardial infarction, and unscheduled revascularization, as well as hospital length of
stay, and readmission to the hospital. We will contact the patients at 6 months to determine if the early effects
on mortality are sustained or possibly enhanced.
Relevance
MINT is positioned to determine the threshold for blood transfusions in patients with acute myocardial infarction
to minimize death and subsequent heart attacks. Given the high incidence of acute myocardial infarction, the
results of MINT can shape clinical practice.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Core 3: Data Collection & Data Management Core
-
批准号:10471455
-
项目类别:
-
资助金额:$355.33万
-
财政年份:2020
-
负责人:Maria Mori Brooks
-
依托单位:
Core 1: Administrative Core
-
批准号:10471453
-
项目类别:
-
资助金额:$123.46万
-
财政年份:2020
-
负责人:Maria Mori Brooks
-
依托单位:
The Study of Women's Health Across the Nation (SWAN): The Impact of Midlife and the Menopause Transition on Health and Functioning in Early Old Age
-
批准号:10911525
-
项目类别:
-
资助金额:$11.36万
-
财政年份:2020
-
负责人:Maria Mori Brooks
-
依托单位:
Core 1: Administrative Core
-
批准号:10263895
-
项目类别:
-
资助金额:$121.92万
-
财政年份:2020
-
负责人:Maria Mori Brooks
-
依托单位:
Core 3: Data Collection & Data Management Core
-
批准号:10263897
-
项目类别:
-
资助金额:$429.92万
-
财政年份:2020
-
负责人:Maria Mori Brooks
-
依托单位:
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
-
批准号:10402934
-
项目类别:
-
资助金额:$78.25万
-
财政年份:2019
-
负责人:Maria Mori Brooks
-
依托单位:
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
-
批准号:10163253
-
项目类别:
-
资助金额:$83.89万
-
财政年份:2019
-
负责人:Maria Mori Brooks
-
依托单位:
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
-
批准号:9926916
-
项目类别:
-
资助金额:$107.83万
-
财政年份:2019
-
负责人:Maria Mori Brooks
-
依托单位:
2/2 Sickle Cell Disease and CardiovAscular Risk - Red cell Exchange Trial (SCD-CARRE Trial)
-
批准号:10642928
-
项目类别:
-
资助金额:$71.5万
-
财政年份:2019
-
负责人:Maria Mori Brooks
-
依托单位:
Treatment and Risk Factor Determinants of Cardiovascular Outcomes in BARI 2D
-
批准号:8625130
-
项目类别:
-
资助金额:$10.91万
-
财政年份:2013
-
负责人:Maria Mori Brooks
-
依托单位:
Study of Women's Health Across the Nation (SWAN) V: Coordinating Center
-
批准号:9108798
-
项目类别:
-
资助金额:$246.22万
-
财政年份:1994
-
负责人:Maria Mori Brooks
-
依托单位:
Study of Women's Health Across the Nation - Coordinating Center
-
批准号:8309211
-
项目类别:
-
资助金额:$205.31万
-
财政年份:1994
-
负责人:Maria Mori Brooks
-
依托单位:
Study of Women's Health Across the Nation - Coordinating Center
-
批准号:8462493
-
项目类别:
-
资助金额:$173.89万
-
财政年份:1994
-
负责人:Maria Mori Brooks
-
依托单位:
Study of Women's Health Across the Nation (SWAN) V: Coordinating Center
-
批准号:8760988
-
项目类别:
-
资助金额:$271.32万
-
财政年份:1994
-
负责人:Maria Mori Brooks
-
依托单位:
海外基金